Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis.

ABSTRACT: Sirt2 is a nicotinamide adenine dinucleotide (NAD⁺)-dependent protein lysine deacylase that can remove both acetyl group and long-chain fatty acyl groups from lysine residues of many proteins. It was reported to affect inflammatory bowel disease (IBD) symptoms in a mouse model. However, conflicting roles were reported, with genetic knockout aggravating while pharmacological inhibition alleviating IBD symptoms. These seemingly conflicting reports cause confusion and deter further efforts in developing Sirt2 inhibitors as a potential treatment strategy for IBD. We investigated these conflicting reports and elucidated the role of Sirt2 in the mouse model of IBD. We essentially replicated these conflicting results and confirmed that Sirt2 inhibitors' protective effect is not through

SUBMITTER: Hou D 

PROVIDER: S-EPMC11066986 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature